Farther Finance Advisors’s Coherus Oncology CHRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$559 Sell
462
-2,058
-82% -$2.81K ﹤0.01% 5731
2026
Q2
$3.53K Buy
2,520
+385
+18% +$629 ﹤0.01% 4962
2026
Q1
$3.71K Buy
2,135
+123
+6% +$218 ﹤0.01% 4637
2025
Q4
$2.86K Buy
+2,012
New +$2.93K ﹤0.01% 4554
2025
Q2
– Sell
-47
Closed -$38 – 4530
2025
Q1
$38 Hold
47
– – ﹤0.01% 4148
2024
Q4
$65 Buy
+47
New +$53 ﹤0.01% 3845
2024
Q2
– Sell
-91
Closed -$218 – 3839
2024
Q1
$218 Buy
91
+88
+2,933% +$217 ﹤0.01% 3251
2023
Q4
$10 Buy
+3
New +$8 ﹤0.01% 3500

Other funds holding CHRS

Farther Finance Advisors's CHRS Position: Q3 2026 in Review

Farther Finance Advisors reduced its Coherus Oncology (CHRS) stake by 82% in Q3 2026, selling an estimated $2.81K and leaving 462 shares worth $559. The position accounts for ﹤0.01% of the portfolio, ranked #5731.

Farther Finance Advisors first reported a position in CHRS in Q4 2023 and has held it in 8 quarters since. The position peaked at $3.71K in Q1 2026. 7 funds tracked by Wall St. Rank hold CHRS as of Q3 2026.

  • Farther Finance Advisors held 462 shares of Coherus Oncology worth $559 as of Q3 2026.
  • Farther Finance Advisors sold 2,058 Coherus Oncology shares in Q3 2026, an estimated $2.81K.
  • Coherus Oncology made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #5731 holding.
  • Farther Finance Advisors first reported a position in Coherus Oncology in Q4 2023 and has held it in 8 quarters since.
  • Farther Finance Advisors's Coherus Oncology position peaked at $3.71K in Q1 2026.
  • 7 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.